

04-70450-02

Original Effective Date: 03/15/04

Reviewed: 05/28/26

Revised: 06/15/26

## Subject: Computed Tomography to Detect Coronary Artery Calcification

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

[Position Statement](#)

[Billing/Coding](#)

[Reimbursement](#)

[Program Exceptions](#)

[Definitions](#)

[Related Guidelines](#)

[Other](#)

[References](#)

[Updates](#)

### DESCRIPTION:

Several types of fast computed tomography (CT) imaging, including electron-beam computed tomography (EBCT) and spiral CT, allow the quantification of calcium in coronary arteries. Coronary artery calcium (CAC) is examined through electron beam computed tomography or multislice computed tomography (CT). Coronary artery calcium (CAC) is associated with coronary artery disease (CAD). The use of CAC scores has been studied in the prediction of future risk of CAD and in the diagnosis of CAD in symptomatic patients.

EBCT software permits quantification of calcium area and density, which are translated into calcium scores. Calcium scores have been investigated as a technique for detecting coronary artery calcification, both as a diagnostic technique in symptomatic patients to rule out an atherosclerotic etiology of symptoms or, in asymptomatic patients, as an adjunctive method for risk stratification for CAD. This guideline addresses the use of coronary artery calcium (CAC) testing in the outpatient setting.

**Summary and Analysis of Evidence:** In an UpToDate review on “Coronary artery calcium scoring (CAC): Overview and clinical utilization” (Kramer) states that “The association between vascular calcification and cardiovascular disease (CVD) is well established. In asymptomatic patients without established atherosclerotic cardiovascular disease (ASCVD), the presence of coronary artery calcification (CAC) on computed tomography (CT) scans is a well-validated measure of subclinical atherosclerosis. The presence of CAC should prompt consideration of aggressive risk factor modification for primary prevention of ASCVD events (including myocardial infarction [MI], stroke, and death from coronary heart disease [CHD]). Advantages of CAC imaging compared with invasive coronary angiography or coronary CT angiography (CCTA) include minimal requirements for patient preparation, no requirement for iodinated intravenous contrast, and relatively low effective radiation doses. Two primary uses of screening for CAC include prediction of atherosclerotic cardiovascular disease (ASCVD) and selection of patients for treatment with aggressive ASCVD risk factor modification (i.e., statin therapy). These suggested uses of CAC scoring, including any therapy based on the results of the CAC scan, are generally in agreement with those of professional societies. CAC scores are usually interpreted in conjunction with other ASCVD risk scoring to guide therapeutic decisions.”

Coronary artery calcium scoring has superior discrimination and risk reclassification as compared with other subclinical imaging markers or biomarkers. In the MultiEthnic Study of Atherosclerosis (MESA) trial, the coronary artery calcium score was strongly associated with 10-year atherosclerotic cardiovascular disease (ASCVD) risk in a graded manner across age, sex, and racial/ethnic groups, independent of traditional risk factors. Coronary artery calcium may even refine ASCVD risk estimates among lower-risk women (<7.5% 10-year risk), younger adults (<45 years of age), and older adults (≥75 years of age), but more data are needed to support its use in these subgroups. A coronary artery calcium score of zero identifies individuals at lower risk of ASCVD events and death over a ≥10-year period, who appear to derive little or no benefit from statins for ASCVD risk reduction. Thus, the absence of coronary artery calcium could reclassify a patient downward into a lower risk group in which preventive interventions (e.g., statins) could be postponed. Note that the absence of coronary artery calcium does not rule out noncalcified plaque, and clinical judgment about risk should prevail. Coronary artery calcium might also be considered in refining risk for selected low-risk adults (<5% 10-year risk), such as those with a strong family history of premature coronary heart disease (CHD). MESA and Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) are risk estimation tools that incorporate both risk factors and coronary artery calcium for estimating 10-year CHD and ASCVD risk, respectively. Coronary artery calcium measurement is not intended as a “screening” test for all but rather may be used as a decision aid in select adults to facilitate the clinician–patient risk discussion (Arnett, 2019).

## POSITION STATEMENT:

Coronary artery calcium (CAC) testing (e.g., electron beam computed tomography (EBCT), ultrafast CT, spiral CT (helical CT)) **meets the definition of medical necessity** for the following indications:

- In the context of shared decision making for members aged 40 to 75 (without clinical atherosclerotic cardiovascular disease), with intermediate-to-low 10-year risk (5 - 20%), with documentation that the coronary artery calcium (CAC) score is necessary to adjust management, such as statin therapy.
- Members who are over 75 or younger than 40 years old can be considered for CAC testing when there is documented evidence that the results could alter management:
  - Members with estimated 10-year risk of less than 5%, but are suspected to be at elevated atherosclerotic cardiovascular disease (ASCVD) risk because of a major risk factor not accounted for in the global risk equations, such as family history of premature coronary artery disease (CAD)
  - Members in whom statin therapy is indicated but have intolerable adverse effects from statin therapy or are reluctant to take statin medication, in order to guide the need for alternative lipid-lowering strategies
- CAC testing may be repeated for risk re-assessment after a minimum of 5 years, if documentation indicates it will alter management. It should not be repeated if the member already has two CAC scores of zero 5 years apart or has a score ≥ 400.

## Online cardiac risk calculator and assessment tools

The links for the online cardiac risk calculator and assessment tools are to an outside source and is provided for your convenience. Use of the links and related calculator and assessment tools are subject to the terms and conditions of the website and is not warranted, maintained or affiliated with Florida Blue.

Framingham Risk Score Calculator

<http://www.medcalc.com/heartrisk.html>

Reynolds Risk Score

<http://www.reynoldsriskscore.org/>

Pooled Cohort Risk Assessment Equations

<http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx>

ACC/AHA Risk Calculator

<http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/>

MESA Risk Calculator (With addition of coronary artery calcium score, for CAD-only risk.)

<https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx>

## CAD Risk

Low < 10%

Moderate 10%-20%

High risk ≥ 20%

## BILLING/CODING INFORMATION:

### CPT Coding:

75571	Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium
-------	---

### HCPCS Coding:

S8092	Electron beam computed tomography (also known as ultrafast CT, cine CT)
-------	---

## REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

## PROGRAM EXCEPTIONS:

**Federal Employee Plan (FEP):** Follow FEP guidelines.

**Medicare Advantage products:** No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline reviewed date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

## DEFINITIONS:

No guideline specific definitions apply.

## RELATED GUIDELINES:

[Computed Tomographic Angiography \(CTA\) Heart, 04-70450-03](#)

## OTHER:

**Note:** The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Cine Computed X-ray Tomography

Computed X-ray Tomography

Coronary Calcium Scan

Coronary Artery Calcium Scoring (CACS)

Electron Beam Computed Tomography (EBCT)

Electron Beam CT

Electron Beam Tomography (EBT)

HeartScan

High-Speed Rapid Acquisition X-ray Computed Tomography

Spiral Computed Tomography (Spiral CT) (Helical Computed Tomography Scanning)

Ultrafast Computed Tomography (Ultrafast CT)

## REFERENCES:

1. ACR-NASCI-SPR Practice Parameter for the Performance and interpretation of Cardiac Computed Tomography (CT), 2016 .
2. Arnett DK, Blumenthal S, Albert NA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 140 (11): e596-e646.
3. Blaha MJ, Cainzos-Acirica M, Greenland P et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation* March 2016; 133 (9): 849-858.
4. Blankstein R, Gupta A, Rana J, et al. The implication of coronary artery calcium testing for cardiovascular disease prevention and diabetes. *Endocrinology and Metabolism* 2017; 32:47-57.
5. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. *Circulation*. Oct 17 2006;114(16):1761-1791.
6. Budoff MJ, Shaw LJ, Liu ST et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. *Journal of the American College of Cardiology* 2007; 49: 1860-1870.
7. Clouse ME. How useful is computed tomography for screening for coronary artery disease? *Circulation* 2006; 113: 124-146.
8. Elkeles RS, Godsland IF, Feher MD et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. *European Heart Journal* 2008; 29(18): 2244-2251.
9. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular

- Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Journal of the American College of Cardiology*. Nov 4 2014;64(18):1929-1949.
10. Gepner AD, Young R, Delaney JA et al. Comparison of Carotid Plaque Score and Coronary Artery Calcium Score for Predicting Cardiovascular Disease Events: The Multi-Ethnic Study of Atherosclerosis. *Journal of the American Heart Association* Feb 2017; 6(2).
  11. Goff DC, Lloyd-Jones, DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014; 129 (25 Suppl 2): S49-S73.
  12. Gottlieb I, Miller JM, Arbab-Zadeh A, et al. The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography. *Journal of the American College of Cardiology*. Feb 16 2010;55(7):627-634.
  13. Greenland P, Blaha MJ, Budoff MJ, et al. Coronary Calcium Score and Cardiovascular Risk. *J Am Coll Cardiol* 2018; 72(4):434–447.
  14. Greenland et al. ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients with Chest Pain. *Circulation* 2007; 115; 402 -426.
  15. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol*. Jan 23 2007;49(3):378-402.
  16. Greenland P, LaBree L, Azen S et al. Coronary Artery Calcium Combined with Framingham Score for Risk Prediction in Asymptomatic Individuals. *The Journal of the American Medical Association (JAMA)* 2004; 291(2): 210-215.
  17. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021 Nov 30;144(22):e368-e454.
  18. Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. *Journal of Cardiovascular Computed Tomography* 2017; 11(2):157-168 (Abstract).
  19. Jacobs PC, Gondrie MJ, van der Graaf Y, et al. Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer. *AJR. American Journal of Roentgenology*. March 2012;198(3):505-511.
  20. Kramer CM, Villines TC. Coronary artery calcium scoring (CAC): Overview and clinical utilization. In: *UpToDate*, Post TW (Ed), *UpToDate*, Waltham, MA. (Accessed on February 19, 2024.)
  21. Lakoski SG, Greenland P, Wong ND et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). *Archives of Internal Medicine* 2007; 167(22): 2437-24442.
  22. Lin JS, Evans CV, Johnson E et al. US Preventive Services Task Force Evidence Summary Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2018; 320(3): 281-297.
  23. Mahabadi AA, Hohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC Primary Prevention Guideline. *JACC Cardiovascular Imaging*. 2017; 10(2):143-153.

24. McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). *J Am Coll Cardiol* 2015; 66(15):1643-1653.
25. Michos ED, Blaha MJ, Blumenthal RS. Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. *Mayo Clin Proc.* 2017 Dec;92(12):1831-1841.
26. Mozaffarian D. Electron-Beam Computed Tomography for Coronary Calcium A Useful Test to Screen for Coronary Heart Disease? *The Journal of the American Medical Association (JAMA)* 2005; 294(22): 2897-2901.
27. Nakanishi R, Li D, Blaha MJ et al. All-cause mortality by age and gender based on coronary artery calcium scores. *European Heart Journal Cardiovascular Imaging.* Nov 2016; 17 (11): 1305-1314.
28. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol* 2015; 66(15):1657-1668.
29. O'Malley PG, Feuerstein IM, Taylor AJ. Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial. *JAMA* 2003; 289(17): 2215-2223.
30. Pender A, Lloyd-Jones DM, Stone NJ, et al. Refining statin prescribing in lower-risk individuals, informing risk/benefit decisions. *J Am Coll Cardiol* 2016; 68(15):1690-1697.
31. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). *European Heart Journal.* 2016; 37:2315–2381.
32. Pursnani A, Chou ET, Zakrofsky P, et al. Use of coronary artery calcium scanning beyond coronary computed tomographic angiography in the emergency department evaluation for acute chest pain: the ROMICAT II trial. *Circulation Cardiovascular Imaging.* March 2015;8(3).
33. Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. *Journal of the American College of Cardiology.* April 2011;57(15):1622-1632.
34. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol.* Nov 23 2010;56(22):1864-1894.
35. Whelton SP, Nasir K, Blaha MJ et al. Coronary artery calcium and primary prevention risk assessment: what is the evidence? An updated meta-analysis on patient and physician behavior. *Circulation Cardiovascular Quality Outcomes* July 2012; 5 (4): 601-607.
36. Won KB, Chang HJ, Niinuma H, et al. Evaluation of the predictive value of coronary artery calcium score for obstructive coronary artery disease in asymptomatic Korean patients with type 2 diabetes mellitus. *Coronary Artery Disease.* March 2015;26(2): 150-156.

## COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 05/28/26.

## GUIDELINE UPDATE INFORMATION:

03/15/04	New Medical Coverage Guideline.
03/15/05	Scheduled review, no change in coverage statement, and updated references.
01/15/06	HCPCS update, added 0144T. Updated references.
03/15/06	Updated references.
03/15/07	Scheduled review, no change in coverage statement, and updated references.
06/15/07	Reformatted guideline.
07/01/07	Updated Program Exceptions.
01/21/08	Updated Program Exceptions.
03/15/08	Scheduled review; no change in position statement. Revised 0144T code descriptor. Added coronary calcium scan to other section, and updated references.
03/15/09	Scheduled review. No change in position statement (experimental or investigational), and updated references.
05/21/09	Removed Federal Employee Plan (FEP) from BCBSF Radiology Management program exception statement. Added FEP program exception statement: FEP is excluded from the National Imaging Associates (NIA) review; follow FEP guidelines.
07/01/09	Updated BCBSF Radiology Management program exception; added BlueSelect.
01/01/10	Annual HCPCS coding update: deleted 0144T. Added 75571. Revised BCBSF Radiology Management program exception section.
03/15/10	Scheduled review. No change in position statement (experimental or investigational), and updated references.
03/15/12	Scheduled review. No change in position statement. Updated references.
12/15/12	Added Medicare program exception. Added Computed Tomographic Angiography (CTA), 04-70450-03 to related guidelines section.
05/11/14	Revision: Program Exceptions section updated.
02/15/15	Annual review. No change in position statement.
11/01/15	Revision: ICD-9 Codes deleted.
06/15/18	Review; revised position statement. Updated description and references.
10/15/20	Review; revised position statement. Added indications and criteria for coronary artery calcium (CAC) testing. Updated description and references.
05/15/22	Review; no change in position statement. Updated description, program exception, and references.
07/01/22	Revision to Program Exceptions section.
06/10/23	Review; no change in position statement. Updated references
08/21/23	Update to Program Exceptions section.

06/15/24	Review; no change in position statement. Updated program exceptions and references.
06/15/25	Review; no change in position statement.
06/15/26	Review; no change in position statement.